Uveal Melanoma: Adjuvant Therapy View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2019-06-29

AUTHORS

Jessica Yang , Elaine Binkley , Arun D. Singh , Richard D. Carvajal

ABSTRACT

Uveal melanoma is a rare, aggressive cancer arising from melanocytes of the uveal tract. It is the most common primary intraocular malignancy in adults. Despite excellent rates of local disease control, nearly 50% of patients will develop metastatic disease, with the most common initial site being the liver. Outcomes are exceedingly poor following the development of distant disease, with a median survival ranging from 4 to 15 months. Advances in molecular profiling have enabled a more accurate prediction of metastatic risk. Given the poor prognosis associated with metastatic disease, the development of effective adjuvant therapies is critical to the management of high-risk patients. In this chapter, we provide a comprehensive review of historical, current, and future approaches to adjuvant therapy including chemotherapy, targeted therapy, immunotherapy, epigenetic drugs, liver-directed therapy, and other novel treatment strategies. More... »

PAGES

305-315

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-030-17879-6_21

DOI

http://dx.doi.org/10.1007/978-3-030-17879-6_21

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1117637069


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.239585.0", 
          "name": [
            "Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yang", 
        "givenName": "Jessica", 
        "id": "sg:person.012452126060.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012452126060.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.239578.2", 
          "name": [
            "Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Binkley", 
        "givenName": "Elaine", 
        "id": "sg:person.0634724713.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634724713.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.239578.2", 
          "name": [
            "Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Singh", 
        "givenName": "Arun D.", 
        "id": "sg:person.01223747053.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223747053.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.239585.0", 
          "name": [
            "Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carvajal", 
        "givenName": "Richard D.", 
        "id": "sg:person.0726366600.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2019-06-29", 
    "datePublishedReg": "2019-06-29", 
    "description": "Uveal melanoma is a rare, aggressive cancer arising from melanocytes of the uveal tract. It is the most common primary intraocular malignancy in adults. Despite excellent rates of local disease control, nearly 50% of patients will develop metastatic disease, with the most common initial site being the liver. Outcomes are exceedingly poor following the development of distant disease, with a median survival ranging from 4 to 15\u00a0months. Advances in molecular profiling have enabled a more accurate prediction of metastatic risk. Given the poor prognosis associated with metastatic disease, the development of effective adjuvant therapies is critical to the management of high-risk patients. In this chapter, we provide a comprehensive review of historical, current, and future approaches to adjuvant therapy including chemotherapy, targeted therapy, immunotherapy, epigenetic drugs, liver-directed therapy, and other novel treatment strategies.", 
    "editor": [
      {
        "familyName": "Damato", 
        "givenName": "Bertil E.", 
        "type": "Person"
      }, 
      {
        "familyName": "Singh", 
        "givenName": "Arun D.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-030-17879-6_21", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-030-17878-9", 
        "978-3-030-17879-6"
      ], 
      "name": "Clinical Ophthalmic Oncology", 
      "type": "Book"
    }, 
    "keywords": [
      "adjuvant therapy", 
      "metastatic disease", 
      "common primary intraocular malignancy", 
      "common initial site", 
      "local disease control", 
      "liver-directed therapies", 
      "effective adjuvant therapy", 
      "high-risk patients", 
      "primary intraocular malignancy", 
      "novel treatment strategies", 
      "distant disease", 
      "median survival", 
      "uveal tract", 
      "poor prognosis", 
      "metastatic risk", 
      "treatment strategies", 
      "intraocular malignancy", 
      "uveal melanoma", 
      "aggressive cancer", 
      "therapy", 
      "disease control", 
      "molecular profiling", 
      "disease", 
      "excellent rate", 
      "patients", 
      "initial site", 
      "epigenetic drugs", 
      "future approaches", 
      "immunotherapy", 
      "chemotherapy", 
      "prognosis", 
      "malignancy", 
      "melanoma", 
      "cancer", 
      "liver", 
      "tract", 
      "comprehensive review", 
      "months", 
      "drugs", 
      "survival", 
      "adults", 
      "outcomes", 
      "risk", 
      "melanocytes", 
      "review", 
      "management", 
      "control", 
      "development", 
      "profiling", 
      "rate", 
      "advances", 
      "strategies", 
      "sites", 
      "approach", 
      "chapter", 
      "accurate prediction", 
      "prediction"
    ], 
    "name": "Uveal Melanoma: Adjuvant Therapy", 
    "pagination": "305-315", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1117637069"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-030-17879-6_21"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-030-17879-6_21", 
      "https://app.dimensions.ai/details/publication/pub.1117637069"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-11-24T21:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/chapter/chapter_206.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-030-17879-6_21"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-17879-6_21'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-17879-6_21'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-17879-6_21'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-17879-6_21'


 

This table displays all metadata directly associated to this object as RDF triples.

145 TRIPLES      22 PREDICATES      80 URIs      73 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-030-17879-6_21 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nddb1a31aaf5c4b9a8779a6e9c37ff568
4 schema:datePublished 2019-06-29
5 schema:datePublishedReg 2019-06-29
6 schema:description Uveal melanoma is a rare, aggressive cancer arising from melanocytes of the uveal tract. It is the most common primary intraocular malignancy in adults. Despite excellent rates of local disease control, nearly 50% of patients will develop metastatic disease, with the most common initial site being the liver. Outcomes are exceedingly poor following the development of distant disease, with a median survival ranging from 4 to 15 months. Advances in molecular profiling have enabled a more accurate prediction of metastatic risk. Given the poor prognosis associated with metastatic disease, the development of effective adjuvant therapies is critical to the management of high-risk patients. In this chapter, we provide a comprehensive review of historical, current, and future approaches to adjuvant therapy including chemotherapy, targeted therapy, immunotherapy, epigenetic drugs, liver-directed therapy, and other novel treatment strategies.
7 schema:editor N317a02333be54772956d4efff202ea23
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf Nc1f92cb3c5b841b39dcd40e363bbf297
11 schema:keywords accurate prediction
12 adjuvant therapy
13 adults
14 advances
15 aggressive cancer
16 approach
17 cancer
18 chapter
19 chemotherapy
20 common initial site
21 common primary intraocular malignancy
22 comprehensive review
23 control
24 development
25 disease
26 disease control
27 distant disease
28 drugs
29 effective adjuvant therapy
30 epigenetic drugs
31 excellent rate
32 future approaches
33 high-risk patients
34 immunotherapy
35 initial site
36 intraocular malignancy
37 liver
38 liver-directed therapies
39 local disease control
40 malignancy
41 management
42 median survival
43 melanocytes
44 melanoma
45 metastatic disease
46 metastatic risk
47 molecular profiling
48 months
49 novel treatment strategies
50 outcomes
51 patients
52 poor prognosis
53 prediction
54 primary intraocular malignancy
55 profiling
56 prognosis
57 rate
58 review
59 risk
60 sites
61 strategies
62 survival
63 therapy
64 tract
65 treatment strategies
66 uveal melanoma
67 uveal tract
68 schema:name Uveal Melanoma: Adjuvant Therapy
69 schema:pagination 305-315
70 schema:productId N2dabf1d3c9c445d2a9a0707b07da46b3
71 N423e7f2e60ad4359b5c76da05ab11265
72 schema:publisher Ncb25e69147d74fdfa60becb1de20e2bb
73 schema:sameAs https://app.dimensions.ai/details/publication/pub.1117637069
74 https://doi.org/10.1007/978-3-030-17879-6_21
75 schema:sdDatePublished 2022-11-24T21:13
76 schema:sdLicense https://scigraph.springernature.com/explorer/license/
77 schema:sdPublisher Ncbfed29b2ad449bc89fea4699dc5a9ea
78 schema:url https://doi.org/10.1007/978-3-030-17879-6_21
79 sgo:license sg:explorer/license/
80 sgo:sdDataset chapters
81 rdf:type schema:Chapter
82 N2dabf1d3c9c445d2a9a0707b07da46b3 schema:name doi
83 schema:value 10.1007/978-3-030-17879-6_21
84 rdf:type schema:PropertyValue
85 N317a02333be54772956d4efff202ea23 rdf:first N5d06fff8ad3d4f98968d084ced40cccb
86 rdf:rest N96111708430743738a5e00991057fd55
87 N423e7f2e60ad4359b5c76da05ab11265 schema:name dimensions_id
88 schema:value pub.1117637069
89 rdf:type schema:PropertyValue
90 N479fa5ff49334c58910fb6220237ae5f rdf:first sg:person.01223747053.67
91 rdf:rest Nc0c3771b69ec44d083af637420bb36d3
92 N5d06fff8ad3d4f98968d084ced40cccb schema:familyName Damato
93 schema:givenName Bertil E.
94 rdf:type schema:Person
95 N6e2a0ba421f74c5bbc07442efe8a0376 rdf:first sg:person.0634724713.60
96 rdf:rest N479fa5ff49334c58910fb6220237ae5f
97 N76d37b7a2df8445db653690b95eafaed schema:familyName Singh
98 schema:givenName Arun D.
99 rdf:type schema:Person
100 N96111708430743738a5e00991057fd55 rdf:first N76d37b7a2df8445db653690b95eafaed
101 rdf:rest rdf:nil
102 Nc0c3771b69ec44d083af637420bb36d3 rdf:first sg:person.0726366600.25
103 rdf:rest rdf:nil
104 Nc1f92cb3c5b841b39dcd40e363bbf297 schema:isbn 978-3-030-17878-9
105 978-3-030-17879-6
106 schema:name Clinical Ophthalmic Oncology
107 rdf:type schema:Book
108 Ncb25e69147d74fdfa60becb1de20e2bb schema:name Springer Nature
109 rdf:type schema:Organisation
110 Ncbfed29b2ad449bc89fea4699dc5a9ea schema:name Springer Nature - SN SciGraph project
111 rdf:type schema:Organization
112 Nddb1a31aaf5c4b9a8779a6e9c37ff568 rdf:first sg:person.012452126060.89
113 rdf:rest N6e2a0ba421f74c5bbc07442efe8a0376
114 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
115 schema:name Medical and Health Sciences
116 rdf:type schema:DefinedTerm
117 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
118 schema:name Oncology and Carcinogenesis
119 rdf:type schema:DefinedTerm
120 sg:person.01223747053.67 schema:affiliation grid-institutes:grid.239578.2
121 schema:familyName Singh
122 schema:givenName Arun D.
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223747053.67
124 rdf:type schema:Person
125 sg:person.012452126060.89 schema:affiliation grid-institutes:grid.239585.0
126 schema:familyName Yang
127 schema:givenName Jessica
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012452126060.89
129 rdf:type schema:Person
130 sg:person.0634724713.60 schema:affiliation grid-institutes:grid.239578.2
131 schema:familyName Binkley
132 schema:givenName Elaine
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634724713.60
134 rdf:type schema:Person
135 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.239585.0
136 schema:familyName Carvajal
137 schema:givenName Richard D.
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
139 rdf:type schema:Person
140 grid-institutes:grid.239578.2 schema:alternateName Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA
141 schema:name Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA
142 rdf:type schema:Organization
143 grid-institutes:grid.239585.0 schema:alternateName Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA
144 schema:name Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA
145 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...